For Healthcare Professionals Outside the US
EXJADE® (deferasirox) film-coated tablets provides efficacy and safety in a convenient once-daily oral tablet
Simplified administration
Proven Efficacy
Improved Adherence
Indications
EXJADE is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 mL/kg/month of packed red blood cells) in patients with beta thalassemia major aged 6 years and older.
EXJADE is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:
EXJADE is also indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with nontransfusion-dependent thalassemia syndromes aged 10 years and older.
Please note: In some countries, EXJADE film-coated tablets is available as JADENU® (deferasirox) tablets.